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ExtErnal ventricular drainage (EVD) is used to con-trol raised CSF pressure after head injury, intracra-nial hemorrhage, or tumor, or as part of the man-
agement of hydrocephalus shunt infection. The ventricular 
catheter in EVD may be in place for a few days or up to 
2–3 weeks, until no longer needed or until malfunction or 
infection occurs. As the system is not totally internalized, 
and as CSF is often drawn from it for analysis and pres-
sure monitoring, the risk of infection is high, with rates 
of up to 20% having been reported.1,3,11 EVD ventriculi-
tis is associated with microbial colonization and biofilm 
formation in the catheter.19 The most common causes of 
EVD ventriculitis are staphylococci of skin origin. Ven-
triculitis has serious consequences for the patient, lead-
ing to poor outcome of the original illness and reduced 
mental and physical capacity, with implications for edu-
cation and employment. It can also lead to scarring and 
loculation of the ventricular system and difficulty in fur-
ther pressure management.17 Due to the initial reason for 
EVD, patients often already have impaired consciousness 
abbreviations EVD = external ventricular drainage; HPLC = high performance liquid chromatography; LC-MS = liquid chromatography–mass spectrometry; MIC = 
minimum inhibitory concentration.
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obJect Recently concern has arisen over the effect of released antimicrobial agents from antibiotic-impregnated ex-
ternal ventricular drainage (EVD) catheters on the reliability of CSF culture for diagnosis of ventriculitis. The authors de-
signed a laboratory study to investigate this possibility, and to determine whether there was also a risk of loss of bacterial 
viability when CSF samples were delayed in transport to the laboratory.
methods Three types of commercially available antibiotic-impregnated EVD catheters were perfused with a sus-
pension of bacteria (Staphylococcus epidermidis) over 21 days. Samples were analyzed for bacterial viability and for 
concentrations of antibiotics released from the catheters. The authors also investigated the effect on bacterial viability in 
samples stored at 18°C and 4°C to simulate delay in CSF samples reaching the laboratory for analysis.
results Bacterial viability was significantly reduced in all 3 catheter types when sampled on Day 1, but this effect 
was not observed in later samples. The results were reflected in stored samples, with significant loss of viability in Day 
1 samples but with little further loss of viable bacteria in samples obtained after this time point. All samples stored for 18 
hours showed significant loss of viable bacteria.
conclusions While there were differences between the catheters, only samples taken on Day 1 showed a signifi-
cant reduction in the numbers of viable bacteria after passing through the catheters. This reduction coincided with higher 
concentrations of antimicrobial agents in the first few hours after perfusion began. Similarly, bacterial viability declined 
significantly after storage of Day 1 samples, but only slightly in samples obtained thereafter. The results indicate that 
drugs released from these antimicrobial catheters are unlikely to affect the diagnosis of ventriculitis, as sampling for this 
purpose is not usually conducted in the first 24 hours of EVD.
http://thejns.org/doi/abs/10.3171/2014.12.JNS141900
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and other neurological symptoms that make diagnosis of 
ventriculitis difficult. This is made even more problem-
atic as laboratory parameters such as CSF inflammatory 
indicators (white blood cell count, lactate levels, etc.) are 
often already abnormal, and blood in the CSF, as from a 
hemorrhage, may also give rise to fever.4,12 The usual cri-
teria for infection are therefore confounded by the initial 
pathology, and the only reliable criterion is isolation of a 
microorganism from the ventricular CSF drawn from the 
EVD catheter.12,20 In some units CSF is routinely drawn 
after 3 or 5 days to check for the presence of bacteria, 
while in other units samples are drawn only when there is 
a clinical concern.6
In recent years, antibiotic-impregnated EVD catheters 
have been introduced in an attempt to reduce the risk of 
ventriculitis arising from catheter colonization.10,21–23 Al-
though these new catheters have been reported to be suc-
cessful in this respect, a recent study18 raised concern that 
antimicrobial agents leaching from the catheters might in-
hibit or kill bacteria in CSF samples, thus producing false-
negative laboratory cultures and masking cases of ven-
triculitis, thereby interfering with or delaying treatment.
Although this is obviously a very important question, 
we consider that the methods used in the previous study 
could be improved and the question extended to cover 
important ancillary questions. We consider it important 
to extend the study to beyond the first 24 hours of per-
fusion, and we were also interested in determining the 
longer-term effect of any antibiotic wash-off on survival 
of bacteria in samples that were not analyzed promptly. 
We also wished to include 2 alternative impregnated cath-
eters in addition to the one used in the previous study. We 
therefore set out to measure drug release in antibiotic-im-
pregnated catheters to determine its effect on viability of 
bacteria passing through the catheters, and to determine 
whether it might affect bacterial viability in samples that 
are delayed in transit to the laboratory.
methods
evd catheters
Ventriclear II G44130 catheters impregnated with ri-
fampicin and minocycline were purchased from Medtron-
ic. Bactiseal barium-filled (82-1749) and Bactiseal clear 
(82-1750) catheters, both impregnated with rifampicin and 
clindamycin, were donated by Codman and Shurtleff, Inc. 
The catheters will be referred to as Ventriclear, Bactiseal 
NC (for barium-filled), and Bactiseal C (for clear). Plain 
medical-grade silicone tubing (Dow Corning Europe) was 
used as a control.
test bacterium
The bacterium used was a strain of Staphylococcus epi-
dermidis (F1228) isolated from a CSF shunt infection. Its 
identification profile by the API Staph System (bioMéri-
eux) was 6606013, and it was susceptible to rifampicin 
(0.008 mg/L), clindamycin (0.125 mg/L), and minocycline 
(0.125 mg/L). The minimum inhibitory concentration 
(MIC) values were determined by Etest (bioMérieux).
catheter perfusion system
Catheters were mounted in hydrated conditions at 37°C 
in an established perfusion system.2 Briefly, this system 
consisted of a modular array of water jackets through 
which the catheters were inserted aseptically before the 
addition of sterile water. The whole modular array was 
encased in an outer water jacket fed by a heat circula-
tor kept at 37°C. The catheters were perfused with ster-
ile physiological saline solution from a reservoir using a 
Watson-Marlow peristaltic pump at a rate of 20 ml/hr, and 
perfusate drained into a second reservoir. The system was 
a single-pass system and did not recirculate the perfusate. 
All 3 types of catheters were tested at one time, each in 
triplicate. Samples of perfusate were aseptically collected 
from the catheters at intervals.
inoculation of the system
On Days 1, 4, 10, and 21, S. epidermidis was added (to 
give a final concentration of 1 × 103 cfu/ml) to the pre-
pump perfusate reservoir so that the bacterial suspension 
passed through all catheters.
sampling regimen
Perfusate (3.5 ml) was sampled from the catheters im-
mediately after introduction of S. epidermidis to the sys-
tem on each of the 4 inoculation days. Each sample was 
assayed quantitatively for bacterial viability by spreading 
200 μl immediately onto each of 3 blood agar culture 
plates. The samples were then divided and 1 held at 4°C 
and the other at 18°C to simulate delay in delivery to the 
laboratory. Each of these samples was plated as described 
after 30 minutes and after 1, 2, 4, and 18 hours of storage 
for bacterial survival. All bacteria surviving after passage 
through the catheters were tested for emergence of resis-
tance to the 3 drugs.
drug concentration assays
The concentration of rifampicin and minocycline for 
each daily sample was assayed by reverse phase–high per-
formance liquid chromatography (HPLC, with an Eclipse 
XDB-C8 column: Agilent Technologies) and liquid chro-
matography–mass spectrometry (LC-MS). Column tem-
perature was 40°C, the volume of injection was 100 μl, 
and the flow rate was 1.0 ml/min. Chromatograms were re-
corded at 333 nm (rifampicin) and 350 nm (minocycline).
A fast (5-minute cycle), sensitive LC-MS method for 
clindamycin was developed (4000 Qtrap, AB Sciex, with 
a Shimadzu VP HPLC). A single channel was used for the 
multiple-reaction monitoring assay, with parent and prod-
uct ion pair (m/z) 426.00 > 126.10 in positive ion electro-
spray mode. The declustering potential was 35 V and the 
collision energy was 23 V. The desolvation temperature 
was 500°C, and the curtain, desolvation, and nebulizer 
gases were set to 20, 30, and 10 units, respectively. An Agi-
lent ZORBAX SB-C18 column was used (column dimen-
sions 2.1 × 50 mm, 1.8 μm) at 50°C with a ballistic gra-
dient; the mobile phase consisted of 80% water to 100% 
methanol (both modified with 0.01% trifluoroacetic acid).
results
bacterial viability on passage through the catheters
Perfusates obtained on Day 1 and assayed immediately 
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(0 minute, Tables 1 and 2) all showed a reduction in the 
number of viable bacteria passing through the catheters 
compared with controls. This reduction was greatest for 
the two Bactiseal catheters, with the clear silicone version 
(Bactiseal C) providing the largest reduction. Perfusates 
obtained on subsequent days (4, 10, and 21) and assayed 
immediately showed insignificant reductions (approxi-
mately 2%–3%) for the 2 Bactiseal catheters but a 13% 
reduction for the Ventriclear catheter.
storage of perfusates at 18°c
When perfusates were stored at 18°C (Table 1), those 
from the control catheters showed little reduction in bacte-
rial viability for 4 hours, but at 18 hours there was an ap-
proximately 90% reduction. For Bactiseal C, on Day 1 of 
sampling there was a considerable decrease in viable bac-
teria to 12.2% of the control value, which was sustained 
when samples were stored for up to 4 hours. There was a 
less dramatic decrease in viability in Day 1 samples for 
Bactiseal NC (to 45% of control value), and this had de-
creased to 20.4% after storage for 4 hours. The decrease 
in bacterial viability for Day 1 samples from Ventriclear 
was far smaller (to 73.5% of control value), and this fell 
to 37.8% after storage for 4 hours. In later samples, loss 
of viability was not significant in either type of Bactiseal 
catheter (to 98%–99%) and the loss on storage for 4 hours 
was not significant, but for later samples from the Ventri-
clear catheters there was a decrease in bacterial viability 
to 87.1% of controls and a slightly further decrease to 85% 
after storage for 4 hours.
Bacterial viability after storage at this temperature for 
18 hours was low in all catheters and similar to control 
values for that storage period. The difference in viable 
bacteria count for the two Bactiseal catheters from the 
controls for samples after Day 1 was not statistically sig-
nificant, but it was significant for controls compared with 
the Ventriclear catheter (p = 0.046).
storage of perfusates at 4°c
When stored at 4°C (Table 2), the perfusates from con-
trol catheters showed less reduction in bacterial viability 
after 18 hours than those stored at the higher temperature, 
but it was still > 60%. For the 3 antibiotic-impregnated 
catheters, the loss in viability was similar to that found at 
18°C.
assays of drug concentrations in perfusates
Mean concentrations of rifampicin from Bactiseal C, 
Bactiseal NC, and Ventriclear catheters for perfusates col-
lected immediately (time = 0) on Day 1 were 3.25 mg/L, 
0.39 mg/L, and 0.31 mg/L, respectively. Mean concentra-
tions of clindamycin in these samples for Bactiseal C were 
table 1. percentage viability of bacteria after passing through 





Time of Storage (hrs)
0 0.5 1 2 4 18
Control
 1 100 98.6 96.5 95.5 94 10.2
 4 100 99.4 96.7 96.5 95.9 9.6
10 100 99.4 97.6 96.5 95.9 10.2
21 100 97.9 97.7 96.7 95.7 9.5
Bactiseal C
 1 12.2 12.2 12.2 12.2 12.2 0
 4 98.2 96.9 96.7 96.5 96.5 9.3
10 98.2 98.2 98 95.5 92.9 9.3
21 97.9 96.1 95.5 94.3 91.4 8.9
Bactiseal NC
 1 44.9 30.6 28.6 28.6 20.4 0
 4 97.8 97.1 96.9 95.9 95.9 9.6
10 97.8 97.1 96.9 96.7 96.7 9.6
21 96.7 96.3 95.7 95.3 95.3 7.9
Ventriclear
 1 73.5 69.4 69.4 61.2 37.8 0.6
 4 87.1 87.1 87.3 86.1 85.3 8
10 87.1 87.1 87.3 86.1 88.4 8
21 87 87 86.2 87.8 85 7.9
* For all antimicrobial EVDs there was a significant reduction in bacterial via­
bility in the perfusate obtained immediately after beginning perfusion 
(Day 1). Thereafter, the difference in bacterial viability between Bactiseal C 
and Bactiseal NC was not significantly different from control catheters 
(p > 0.05), but the difference was significant for Ventriclear catheters (p < 0.05).
table 2. percentage viability of bacteria after passing through 





Time of Storage (hrs)
0 0.5 1 2 4 18
Control
 1 100 99.6 97.6 96.1 94.9 32.7
 4 100 98.6 96.5 95.5 93.9 37.8
10 100 99.6 98.0 98.2 95.9 34.7
21 100 97.7 97.7 97.7 97.7 33.2
Bactiseal C
 1 12.2 12.2 12.2 12.2 12.2 6.5
 4 99.2 98.4 97.3 97.1 97.1 31.7
10 98.2 98.4 97.1 97.3 97.1 32.7
21 96.9 97.1 95.9 96.1 95.9 32.2
Bactiseal NC
 1 44.9 28.6 28.6 28.6 24.5 8.2
 4 97.8 97.8 97.8 97.8 96.7 34.7
10 97.8 96.9 96.5 95.9 95.1 34.7
21 96.5 96.5 96.5 96.5 95.5 33.2
Ventriclear
 1 73.5 67.3 61.2 59.2 37.8 8.8
 4 87.8 87.8 87.8 85.7 85.3 29.6
10 89.0 89.0 89.0 89.0 88.4 31.5
21 87.6 88.6 88.6 87.8 87.2 29.2
* For all antimicrobial EVDs there was a significant reduction in bacterial viabil-
ity in the perfusate obtained immediately after beginning perfusion on Day 1. 
Upon storage for 4 hours, viability was not further reduced for Bactiseal C but 
was reduced in the case of Bactiseal NC and Ventriclear.
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significantly higher (24.58 mg/L) than for Bactiseal NC 
(6.05 mg/L; p = 0.017). The mean concentration of mino-
cycline at this time point for Ventriclear was 2.57 mg/L. 
However, the concentrations of all drugs in all 3 types of 
catheters fell sharply in the following few hours, and by 
Day 1 or 2 they had reached low plateau levels (Figs. 1–3). 
All assays were performed in triplicate with samples from 
triplicate catheters of each type.
discussion
Because of the reliance on positive CSF cultures for the 
diagnosis of EVD ventriculitis, the possibility that anti-
microbial catheters might interfere with this by inhibiting 
bacterial growth is a serious question. Stevens et al.18 set 
out to address this issue, but their paper can be criticized 
on several methodological points. They used a static meth-
od to fill the EVD catheters with saline and left this in the 
catheters for various lengths of time without any flow. This 
would give different results from those used in our paper, 
which we consider to be more relevant to EVD catheter 
conditions in use. Their study covered only the first 24 
hours, but samples of CSF for diagnosis are unlikely to 
be obtained so early after placement of the catheter, and 
practice varies: some obtain samples at 3 or 5 days, some 
3 times weekly, and some only if clinically indicated,5–7,14 
and clinical concern regarding infection usually does 
not arise so soon as within 24 hours after placement.8,9,15 
The detection method of Stevens et al. for drug release 
(capillary electrophoresis) did not allow quantitative de-
termination of actual drug levels in the saline, whereas 
our methods (HPLC and LC-MS) were able to accurately 
determine the concentrations of drugs in the perfusates 
at each time point. It could also be said that their assay 
for antimicrobial activity, performed by dropping 30 μl of 
sample onto the surfaces of seeded agar plates and mea-
suring the zones after incubation, would lead to variation 
in zone sizes due to inconsistent spread of the droplets. 
Finally, they tested only 1 of the antimicrobial catheter 
types that is commercially available, whereas we tested 
all 3, with the exception of silver-processed catheters that 
would not be expected to elute antimicrobial activity.16 In 
the clinic, CSF samples should be transmitted to the labo-
ratory immediately for prompt examination,13 but in real-
ity they are sometimes delayed for some hours and occa-
sionally until the following day (especially on weekends), 
and they might be placed in a refrigerator until sent. This 
is why we examined the effect of antimicrobials on bacte-
rial viability after storage.
Our results showed that for each of the 3 catheters, 
enough antimicrobial agent was released to affect the vi-
ability of bacteria passing through the catheter on the first 
day and especially in the first few hours. In this respect, 
our results confirm those of Stevens et al.18 However, after 
this time there was a significant decline in drug concentra-
tions to low levels in all catheters. There were important 
differences in results between the catheters tested. The 
amount of rifampicin released from all 3 catheter types 
over the test period of 21 days was broadly similar, but 
the Bactiseal C catheters released approximately 10 times 
as much as the Bactiseal NC and Ventriclear catheters 
Fig. 1. Antimicrobial activity of samples taken daily from Bactiseal C (Bact clear) catheters for 21 days. On Day 1, the concentra-
tion of rifampicin (Rif) released immediately after beginning perfusion was 3.25 mg/L, and the concentration then dropped sig-
nificantly (0.25 mg/L at 30 minutes, 0.14 mg/L at 1 hour, 0.06 mg/L at 2 hours, and 0.08 mg/L at 4 hours). Thereafter (Days 2–21) 
the rifampicin concentration plateaued and was 0.01 mg/L on Day 21. On Day 1, the concentration of clindamycin (Clind) released 
immediately was 24.58 mg/L, and the concentration then dropped significantly (1.39 mg/L at 30 minutes, 1.30 mg/L at 1 hour, 1.08 
mg/L at 2 hours, and 1.21 mg/L at 4 hours). The concentration of clindamycin for samples taken on Days 2–21 plateaued and was 
0.20 mg/L on Day 21.
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Fig. 3. Antimicrobial activity of samples taken daily from Ventriclear catheters for 21 days. On Day 1, the concentration of 
rifampicin (Rif) released immediately was 0.31 mg/L, and the concentration then dropped (0.11 mg/L at 30 minutes, 0.10 mg/L at 
1 hour, 0.08 mg/L at 2 hours, and 0.17 mg/L at 4 hours). Thereafter (Days 2–21), the rifampicin concentration plateaued and was 
0.08 mg/L on Day 21. On Day 1, the concentration of minocyline (Min) released immediately was 2.57 mg/L, and the concentration 
then dropped (1.54 mg/L at 30 minutes, 1.21 mg/L at 1 hour, 1.27 mg/L at 2 hours, and 0.38 mg/L at 4 hours). The concentration of 
minocyline for samples taken daily thereafter (Days 2–21) plateaued and was 0.26 mg/L on Day 21.
Fig. 2. Antimicrobial activity of samples taken daily from Bactiseal NC (Bact non clear) catheters for 21 days. On Day 1, the con-
centration of rifampicin (Rif) released immediately after beginning perfusion was 0.33 mg/L, and the concentration then dropped 
significantly (0.24 mg/L at 30 minutes, 0.25 mg/L at 1 hour, 0.07 mg/L at 2 hours, and 0.04 mg/L at 4 hours). Thereafter (Days 
2–21) the rifampicin concentration plateaued and was 0.05 mg/L on Day 21. On Day 1, the concentration of clindamycin (Clind) re-
leased immediately was 6.05 mg/L, and the concentration then dropped significantly (1.55 mg/L at 30 minutes, 1.16 mg/L at 1 hour, 
0.89 mg/L at 2 hours, and 0.20 mg/L at 4 hours). The concentration of clindamycin for samples taken on Days 2–21 plateaued and 
was 0.16 mg/L on Day 21.
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within the first hour. Again, the amount of clindamycin 
released in this period was significantly higher from the 
Bactiseal C catheters than from the Bactiseal NC cathe-
ters. The drug concentrations in the catheters were identi-
cal (rifampicin 0.25–0.7 mg/g and clindamycin 0.85–1.54 
mg/g; manufacturer’s data sheet), and the dimensions of 
the catheters were also identical. We know of no evidence 
that the inclusion of barium sulfate as a filler in the Bac-
tiseal NC catheters would affect drug release to this extent. 
The difference in drug release is reflected in the bacterial 
viability results for perfusate sampled during this early 
period, in which the reduction in viable count was sig-
nificantly greater for Bactiseal C than for Bactiseal NC 
(and both reduced the viable count more than the Ventri-
clear catheter in this period). However, after this period 
and by Day 4, the effect on viable count of both Bactiseal 
catheters was negligible, whereas there was a persistent 
reduction in viable count for the Ventriclear catheter for 
the entire 21-day period. Referring to the MICs of the 3 
drugs, the test bacterium was inhibited by 0.008 mg/L of 
rifampicin, 0.125 mg/L of clindamycin, and 0.125 mg/L 
of minocycline, and the measured drug levels exceeded 
these throughout. However, after the initial burst period 
the MICs were not greatly exceeded, and the conditions 
in which they were determined (solid medium, Etest) were 
very different from their exposure in fluid medium. Also, 
the Etest determines inhibitory activity, not lethal activity, 
which is likely to account for the survival of susceptible 
bacteria in the perfusates. The effects of storage at differ-
ent temperatures showed no difference between tempera-
tures, but there were differences between catheters at both 
storage temperatures. For the first 4 hours there was neg-
ligible reduction in bacterial viability for both Bactiseal 
catheters for Day 4 samples onward, whereas there was a 
persistent 13%–15% reduction in the case of Ventriclear. 
For all samples stored for 18 hours at both temperatures, 
including those from plain control catheters, there was a 
significant reduction in viable count. This could have been 
influenced by the perfusion medium, physiological saline, 
which lacks the glucose and protein content of CSF.
While our findings confirm those of Stevens et al. for 
the first few hours of drainage, we have shown that for the 
subsequent 21 days there is a negligible effect on bacterial 
viability, both passing through the catheters and in stor-
age, for the Bactiseal catheters. While the effect appears 
greater for Ventriclear catheters, it is doubtful whether this 
is clinically important.
conclusions
Assays of drugs released from antimicrobial catheters 
showed inhibitory levels only on Day 1 of perfusion; there-
after they declined to subinhibitory levels. The effect on 
viability of S. epidermidis passing through the catheters 
was different for each type of catheter, but overall, loss 
of viability was not significant after Day 1. These results 
were reflected in storage of samples to simulate delay in 
transit to the laboratory. It is very unlikely that the high 
drug levels found in the first few hours by us and reported 
by Stevens et al. are clinically relevant, as CSF samples 
are not usually obtained for diagnosis or monitoring for 
infection during this period. It would therefore appear that 
use of none of the 3 catheters is likely to interfere with 
diagnostic CSF culture.
acknowledgment
We are grateful to Mr. Brian Richards, who devised the assay 
protocol.
references
 1. Babu MA, Patel R, Marsh WR, Wijdicks EF: Strategies to 
decrease the risk of ventricular catheter infections: a review 
of the evidence. Neurocrit Care 16:194–202, 2012
 2. Bayston R, Fisher LE, Weber K: An antimicrobial modified 
silicone peritoneal catheter with activity against both Gram-
positive and Gram-negative bacteria. Biomaterials 30:3167–
3173, 2009
 3. Beer R, Lackner P, Pfausler B, Schmutzhard E: Nosocomial 
ventriculitis and meningitis in neurocritical care patients. J 
Neurol 255:1617–1624, 2008
 4. Fernandez A, Schmidt JM, Claassen J, Pavlicova M, Hud-
dleston D, Kreiter KT, et al: Fever after subarachnoid hem-
orrhage: risk factors and impact on outcome. Neurology 
68:1013–1019, 2007
 5. Flint AC, Rao VA, Renda NC, Faigeles BS, Lasman TE, 
Sheridan W: A simple protocol to prevent external ventricu-
lar drain infections. Neurosurgery 72:993–999, 2013
 6. Hader WJ, Steinbok P: The value of routine cultures of the 
cerebrospinal fluid in patients with external ventricular 
drains. Neurosurgery 46:1149–1155, 2000
 7. Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJ: 
Risk factors for infections related to external ventricular 
drainage. Acta Neurochir (Wien) 150:209–214, 2008
 8. Holloway KL, Barnes T, Choi S, Bullock R, Marshall LF, 
Eisenberg HM, et al: Ventriculostomy infections: the effect 
of monitoring duration and catheter exchange in 584 patients. 
J Neurosurg 85:419–424, 1996
 9. Kanter RK, Weiner LB, Patti AM, Robson LK: Infectious 
complications and duration of intracranial pressure monitor-
ing. Crit Care Med 13:837–839, 1985
10. Kubilay Z, Amini S, Fauerbach LL, Archibald L, Friedman 
WA, Layon AJ: Decreasing ventricular infections through the 
use of a ventriculostomy placement bundle: experience at a 
single institution. J Neurosurg 118:514–520, 2013
11. Leverstein-van Hall MA, Hopmans TEM, van der Sprenkel 
JW, Blok HEM, van der Mark WAMA, Hanlo PW, et al: A 
bundle approach to reduce the incidence of external ven-
tricular and lumbar drain-related infections. J Neurosurg 
112:345–353, 2010
12. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr: 
Ventriculostomy-related infections: a critical review of the 
literature. Neurosurgery 51:170–182, 2002
13. Rajesh NT, Dutta S, Prasad R, Narang A: Effect of delay in 
analysis on neonatal cerebrospinal fluid parameters. Arch 
Dis Child Fetal Neonatal Ed 95:F25–F29, 2010
14. Schade RP, Schinkel J, Roelandse FW, Geskus RB, Visser 
LG, van Dijk JMC, et al: Lack of value of routine analysis of 
cerebrospinal fluid for prediction and diagnosis of external 
drainage-related bacterial meningitis. J Neurosurg 104:101–
108, 2006
15. Schultz M, Moore K, Foote AW: Bacterial ventriculitis and 
duration of ventriculostomy catheter insertion. J Neurosci 
Nurs 25:158–164, 1993
16. Secer HI, Kural C, Kaplan M, Kilic A, Duz B, Gonul E, et al: 
Comparison of the efficacies of antibiotic-impregnated and 
silver-impregnated ventricular catheters on the prevention of 
infections. An in vitro laboratory study. Pediatr Neurosurg 
44:444–447, 2008
17. Sonabend AM, Korenfeld Y, Crisman C, Badjatia N, Mayer 
J neurosurg June 12, 20156
drug release from antimicrobial evd catheters
SA, Connolly ES Jr: Prevention of ventriculostomy-related 
infections with prophylactic antibiotics and antibiotic-coated 
external ventricular drains: a systematic review. Neurosur-
gery 68:996–1005, 2011
18. Stevens EA, Palavecino E, Sherertz RJ, Shihabi Z, Couture 
DE: Effects of antibiotic-impregnated external ventricular 
drains on bacterial culture results: an in vitro analysis. J 
Neurosurg 113:86–92, 2010
19. Stoodley P, Braxton EE Jr, Nistico L, Hall-Stoodley L, John-
son S, Quigley M, et al: Direct demonstration of Staphylo-
coccus biofilm in an external ventricular drain in a patient 
with a history of recurrent ventriculoperitoneal shunt failure. 
Pediatr Neurosurg 46:127–132, 2010
20. Sundbärg G, Nordström CH, Söderström S: Complications 
due to prolonged ventricular fluid pressure recording. Br J 
Neurosurg 2:485–495, 1988
21. Tamburrini G, Massimi L, Caldarelli M, Di Rocco C: Anti-
biotic impregnated external ventricular drainage and third 
ventriculostomy in the management of hydrocephalus associ-
ated with posterior cranial fossa tumours. Acta Neurochir 
(Wien) 150:1049–1056, 2008
22. Wong GKC, Ip M, Poon WS, Mak CWK, Ng RYT: Anti-
biotics-impregnated ventricular catheter versus systemic 
antibiotics for prevention of nosocomial CSF and non-CSF 
infections: a prospective randomised clinical trial. J Neurol 
Neurosurg Psychiatry 81:1064–1067, 2010
23. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson 
J, Robertson C, et al: Efficacy of antimicrobial-impregnated 
external ventricular drain catheters: a prospective, random-
ized, controlled trial. J Neurosurg 98:725–730, 2003
author contributions
Conception and design: Bayston. Acquisition of data: Ashraf, 
Ortori. Analysis and interpretation of data: all authors. Drafting 
the article: Bayston, Ortori. Critically revising the article: 
Bayston, Ortori. Reviewed submitted version of manuscript: 
Ashraf, Ortori. Approved the final version of the manuscript on 
behalf of all authors: Bayston. Administrative/technical/material 
support: Ashraf. Study supervision: Bayston.
supplemental information
Previous Presentation
Part of this work was presented orally at the 56th Annual Meeting 
of the Society for Research into Hydrocephalus and Spina Bifida 
in York, United Kingdom, in 2012, and an abstract appeared in 
the program.
correspondence
Roger Bayston, Biomaterials-Related Infection Group, School 
of Medicine, University of Nottingham, Queens Medical Centre, 
C Floor West Block, Nottingham NG7 2UH, United Kingdom. 
email: roger.bayston@nottingham.ac.uk.
J neurosurg June 12, 2015 7
